Logo
Plinest One 5 x 4 ml

Plinest One 5 x 4 ml

Plinest One

Injectable skin booster / biostimulator
  • Part of the Mastelli PN HPT® aesthetic medicine line listed as solution containing Polynucleotides HPT in 5 x 4 ml ampoules.
  • CE Marked Class III medical device based on highly purified polynucleotides (PN HPT®) for intradermal use, manufactured in Italy.
  • Produced under a medical device quality management system compliant with European regulatory standards (e.g. ISO 13485).
Polynucleotide body and skin biorevitalisation solution

Description

Plinest One 5 x 4 ml is a polynucleotide-based injectable solution (PN-HPT® – High Purification Technology) from Mastelli designed for intradermal biorevitalisation, particularly in young patients with early skin laxity and striae distensae (stretch marks). Supplied as five 4 ml vials/ampoules at a concentration of 2 mg/ml PN-HPT®, it provides deep, large-area skin biostimulation for the face, neck, décolletage and body. By delivering highly purified polynucleotides, Plinest One improves turgor, elasticity and tone, enhances hydration and supports intensive skin regeneration and repair without hyaluronic acid, making it ideal for treating lax or stretched skin on the body as well as fine lines and early sagging.

Bnefits

  • Formulated with 2 mg/ml PN-HPT® (High Purification Technology) polynucleotides for powerful dermal biostimulation.
  • Suggested specifically for reducing skin laxity and striae distensae (stretch marks) in young patients.
  • Improves skin turgor, elasticity and overall tone on the face and larger body areas.
  • Deep-acting liquid solution suitable for treating extensive zones such as abdomen, thighs, buttocks and arms as well as face, neck and décolletage.
  • Enhances hydration and skin quality by stimulating fibroblasts and extracellular matrix regeneration.
  • Hyaluronic-acid-free solution, ideal when a non-volumising, regenerative approach is desired.
  • Provided in high-volume 4 ml vials, optimising treatment of body areas and multiple lesions within a single session.
  • Supports intensive skin regeneration and repair in aesthetic and regenerative protocols.

Indications

  • Reduction of skin laxity in young patients, especially in areas prone to early loss of firmness (abdomen, thighs, arms, buttocks).
  • Treatment of striae distensae (stretch marks) in young patients.
  • Biorevitalisation and firming of the face, neck and décolletage.
  • Improving skin quality, elasticity and tone on larger body areas with signs of structural decline or early ageing.
  • Adjunctive treatment in body-contouring or post-weight-loss protocols where dermal support and regeneration are needed.

Composition

  • Polynucleotides PN-HPT® (highly purified polynucleotides) 2 mg/ml (8 mg per 4 ml vial).
  • Sterile, apyrogenic aqueous solution suitable for intradermal injection (additional excipients not specified in publicly available product information).

Formulation

  • Sterile, non-pyrogenic injectable solution containing PN-HPT® polynucleotides.
  • Concentration: 2 mg/ml PN-HPT® in 4 ml vials (8 mg polynucleotides per vial).
  • Presented as a liquid solution (not cross-linked, hyaluronic-acid-free) for intradermal infiltrations.
  • Class III polynucleotide-based biostimulatory medical device intended for professional use only.

Packaging

  • 5 x 4 ml vials/ampoules of Plinest One solution per box.
  • Single-use vials intended for intradermal administration during one or more treatment sessions, according to clinical judgement.
  • Supplied in a branded outer carton with product information and usage guidance for healthcare professionals.

Usage

  • For intradermal use only by suitably trained and qualified healthcare professionals experienced in injectable aesthetic and mesotherapy treatments.
  • Cleanse and disinfect the treatment area (face, neck, décolletage or body regions such as abdomen, thighs or buttocks) in accordance with standard aseptic protocols.
  • Draw the required amount of solution from the 4 ml vial into a sterile syringe fitted with an appropriate fine-gauge needle for intradermal injections.
  • Injection depth: dermal (intradermal), using mesotherapy techniques such as microdroplet, serial puncture or linear retrograde injections, depending on indication and area.
  • Distribute small aliquots of solution evenly over the treatment area, avoiding intravascular injection and respecting anatomical danger zones.
  • Suggested protocol (as listed by multiple distributors): Phase I – one session every 7–14 days for 4 sessions; Phase II – one session every 21–30 days for a further 4 sessions, for a total of 8 sessions.
  • Adjust volume per session and number of treated areas to patient needs, skin condition and clinical goals.
  • Advise patients on post-treatment care, including avoiding excessive sun exposure, heat (sauna, steam), vigorous exercise and topical irritants on the treated area for a short period, as per clinic policy.
  • Discard any unused product in an opened vial at the end of the session; do not reuse. Dispose of vials, syringes and needles in accordance with local sharps and clinical waste regulations.

Contraindications

  • Known hypersensitivity or allergy to polynucleotides or any component of the formulation.
  • Presence of active infection, inflammation, dermatitis or other skin disease at or near the intended injection site.
  • Severe systemic illness, uncontrolled autoimmune disease or coagulation disorders in which injectable procedures are contraindicated unless the risk–benefit has been carefully assessed by a physician.
  • History of severe hypertrophic scarring or keloid formation in or near the treatment area.
  • Pregnancy or breastfeeding, and patients under 18 years of age, due to lack of sufficient safety data.
  • Use by non-medical personnel or self-administration.

Adverse Effects

  • Typical injection-related reactions such as transient redness, swelling, tenderness, bruising or mild pain at injection sites.
  • Temporary papules or small nodules at intradermal injection points, usually resolving spontaneously within a few days.
  • Occasional itching, warmth or mild discomfort in the treated area.
  • As with any intradermal injectable, potential risk of local infection or prolonged inflammatory response if aseptic technique is not strictly observed.
  • Very rare but serious complications such as vascular compromise, tissue ischemia or necrosis may occur if product is inadvertently injected intravascularly or if improper technique is used.

Storage Conditions

  • Store in a cool, dry place away from direct sunlight, within the temperature range indicated on the product packaging (typically controlled room temperature).
  • Do not freeze.
  • Keep vials in their original carton until use to protect from light and contamination.
  • Do not use after the expiry date printed on the packaging or if vials appear damaged or compromised.

Duration

Distributor and clinical protocol information specify an initial course of 8 sessions (Phase I: 4 sessions every 7\u201314 days; Phase II: 4 sessions every 21\u201330 days). Long-term duration of effect is not explicitly stated in manufacturer or distributor materials and typically depends on age, skin quality and lifestyle; maintenance sessions are usually scheduled according to individual response and practitioner judgement.

Onset

Exact onset timing is not explicitly provided in product literature. In clinical practice with PN-HPT\u00ae biostimulators, improvements in hydration and skin feel are generally observed over the first few sessions, with progressive enhancement in firmness, tone and appearance of striae and laxity over the full 8-session protocol.

Browse more Injectable skin booster / biostimulator

Top Treatments

Top Cities in the UK